

Designing and Developing Therapeutic Interventions in the Bioinformatics Era

Norbert Nwankwo*

Department of Bioinformatics, De Montfort University, Leicester, United Kingdom

Discovery, design and development of therapeutic interventions in this dispensation have traversed beyond serendipity [1]. The era of stumbling into active curative agents has been overtaken by the methodological and arduous processes involving laboratory-based investigations, clinical trials, and industrial formulation and production of drugs, vaccines and medical devices.

Laboratory-based clinical investigations involve identification, extraction and isolation of biologically active constituents [2]. This is followed by evaluation of pharmacological activities as well as standardization. Assessment of therapeutic indices (risk-benefit ratio), safety and applicability involve clinical trials, first on animals and then, human. If the therapeutic agent is approved, it is then mass produced depending on the scope of the users. Global ailments such as HIV/AIDS are expected to attract larger production than localized diseases like Malaria, which is a tropical illness. The entire process of discovery, design and development of therapeutic interventions is financial involving [2].

From the fore-going, it is evident that laboratory-based clinical investigations remain pivotal in the successful hunting of any therapeutic intervention. However, these investigations are found to be resource-consuming, expensive and time-wasting [3]. Since serendipity has eluded discovery and designing of therapies, clinical approaches are irrational, and computing knowledge as well as application of artificial intelligence have escalated [1], computer-assisted approaches and robotic devices have therefore crept into the processes of discovery, design and development of therapeutic interventions. The entire processes of hunting for therapies had transited into Computer-Aided Drug Design [4]. This approach to innovating therapies spans from the computer-assisted designing of drug molecules (Molecular Modeling) [5] and Structure-based Modifications [6] to the Absorption, Distribution, Metabolism and Excretion (ADME) [7] assessment and, the large-scale determination of the drug side effects that recently benefitted from the rationality of computation [8]. Other therapeutic interventions that would not have come out of serendipity are the trans-Atlantic surgery [9] and the machine-managed insulin delivery device for the diabetics [10].

As a result of these activities, there is currently, a large deposit of information needed for the discovery, design and development of therapeutic interventions. It has become too challenging to manage these information and therefore, an approach which would help retrieve, organize, analyze these huge data in order to extract, extrapolate, correlate, juxtapose, reconcile and predict outcomes is required. This has brought in Bioinformatics approaches into the invention of therapeutic interventions, which is the only technique that can perform these functions [11].

Bioinformatics tools and programs are bound for these purposes. These devices encompass apparatuses for the search for drug molecules, designing and determination of their potency, resistance and unwarranted effects. The devices involved in the search include High-Throughput Screening (HTS) [12]. Designing involves two

approaches. They are Molecular Modelling [5], which includes Docking [13] and Structure-based optimization [14], where analysis such as Multiple Sequence Alignment [15] and Digital Signal Processing-based [16] are undertaken. Drug resistance algorithms such as Genotype, Phenotype and a combination of both including Virtual Phenotype are Bioinformatics-based.

This journal tends to explore these Bioinformatics techniques that evolved from the Botanic age where herbalists are the bone setters and healers, the all-knowing in therapy.

References

1. Charifson PS (1997) Practical application of computer-aided drug design. Taylor and Francis.
2. Povl KL, Liljefors T, Madsen U (2002) Textbook of Drug Design and Discovery. Taylor and Francis.
3. Bellott EM, Bondaryk R, Luther AL (1997) Combinatorial Chemistry in the Drug Discovery Process. Clin Res Regul Affairs 14: 231-241.
4. Rapaka RS, Hawks RL (1993) Medications Development: Drug Discovery, Databases, and Computer-Aided Drug Design. Citeseer.
5. Cohen NC (1996) Guidebook on Molecular Modelling in Drug Design. Academic Press.
6. Sperandio O, Miteva MA, Villoutreix BO (2008) Combining Ligand- and Structure-Based Methods in Drug Design Projects. Current Computer - Aided Drug Design 4: 250-258.
7. Butina D, Segall MD, Frankcombe K (2002) Predicting ADME Properties in silico: methods and models. Drug Discov Today 7: S83-S88.
8. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, et al. (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 486: 361-367.
9. Kent H (2001) Hands across the ocean for world's first trans-Atlantic surgery. CMAJ 165: 1374.
10. Dolgin E (2012) Medical devices: Managed by machine. Nature 485: S6-S8.
11. Huerta M, Haseltine F, Liu Y, Downing G, Seto B (2000) NIH Working Definition of Bioinformatics and Computational Biology.
12. Carnero A (2006) High throughput screening in drug discovery. Clin Transl Oncol 8: 482-490.
13. Dias R, de Azevedo WF Jr (2008) Molecular docking algorithms. Curr Drug Targets 9: 1040-1047.
14. Hubbard RE (2006) Structure-based drug discovery: An Overview. RBC Publishing.

*Corresponding author: Norbert Nwankwo, Department of Bioinformatics, De Montfort University, Leicester, United Kingdom, E-mail: p07032056@myemail.dmu.ac.uk

Received August 17, 2012; Accepted August 18, 2012; Published August 20, 2012

Citation: Nwankwo N (2013) Designing and Developing Therapeutic Interventions in the Bioinformatics Era. Drug Des 2: e107. doi:10.4172/2169-0138.1000e107

Copyright: © 2013 Nwankwo N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

15. Do CB, Kato K (2008) Protein multiple sequence alignment. *Methods Mol Biol* 484: 379-413.

16. Margaret AD, Thomas EB, Lisa HO, Katherine NKB, Amelia SL, et al.

(2011) Genotypic-phenotypic discrepancies between antibiotic resistance characteristics of *Escherichia coli* from calves in high and low antibiotic use management settings. *Appl Environ Microbiol* 77.